Literature DB >> 20649487

Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?

R M Dwyer1, M J Kerin.   

Abstract

Mesenchymal stem cells (MSCs) are a subset of nonhematopoietic multipotent cells found primarily within the bone marrow stroma. The ability of MSCs to specifically home to sites of tumors and their metastases, while escaping host immune surveillance, holds tremendous promise for tumor-targeted delivery of therapeutic agents. Concerns that MSCs may have an inherent capacity for transformation have led to a number of studies investigating their stability in vitro, as significant ex vivo expansion will be necessary to yield the number of cells required for therapeutic applications. MSCs have also been seen to influence the morphology and proliferation of cells within their vicinity through a combination of cell-to-cell interactions and the secretion of chemoattractant cytokines. Understanding interactions between MSCs and tumor cells is required to support realization of their clinical potential. This review discusses MSCs and cancer in terms of (1) potential for transformation and de novo tumor formation, (2) interactions with epithelial cancer cells in tumor establishment, and (3) potential role after engraftment at the site of an established tumor. Elucidation of any potential negative effect of MSCs in the tumor setting will support development of protocols to minimize these effects while taking full advantage of the remarkable tumor-homing capacity of these cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649487     DOI: 10.1089/hum.2010.135

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  13 in total

1.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

2.  Sigma-2 receptor as potential indicator of stem cell differentiation.

Authors:  Jodi L Haller; Irina Panyutin; Aneeka Chaudhry; Chenbo Zeng; Robert H Mach; Joseph A Frank
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

3.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

4.  Identification and characterization of unique tumoricidal genes in rat umbilical cord matrix stem cells.

Authors:  Deepthi Uppalapati; Naomi Ohta; Yongqing Zhang; Atsushi Kawabata; Marla M Pyle; Kevin G Becker; Deryl Troyer; Masaaki Tamura
Journal:  Mol Pharm       Date:  2011-09-13       Impact factor: 4.939

5.  Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.

Authors:  Youjin Na; Joung-Pyo Nam; JinWoo Hong; Eonju Oh; Ha Cheol Shin; Hyun Soo Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  J Control Release       Date:  2019-05-06       Impact factor: 9.776

6.  Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Authors:  Maria Bunuales; Eva Garcia-Aragoncillo; Raquel Casado; José Ignacio Quetglas; Sandra Hervas-Stubbs; Sergia Bortolanza; Carolina Benavides-Vallve; Carlos Ortiz-de-Solorzano; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

7.  Systemic mesenchymal stem cells reduce growth rate of cisplatin-resistant ovarian cancer.

Authors:  Pengfei Zhu; Mo Chen; Li Wang; Yanxia Ning; Jie Liang; Hao Zhang; Congjian Xu; Sifeng Chen; Liangqing Yao
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

8.  Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer.

Authors:  Jing Ruan; Jiajia Ji; Hua Song; Qirong Qian; Kan Wang; Can Wang; Daxiang Cui
Journal:  Nanoscale Res Lett       Date:  2012-06-18       Impact factor: 4.703

9.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531

10.  Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β.

Authors:  Valentina Mele; Manuele G Muraro; Diego Calabrese; Dennis Pfaff; Nunzia Amatruda; Francesca Amicarella; Brynn Kvinlaug; Chiara Bocelli-Tyndall; Ivan Martin; Therese J Resink; Michael Heberer; Daniel Oertli; Luigi Terracciano; Giulio C Spagnoli; Giandomenica Iezzi
Journal:  Int J Cancer       Date:  2014-01-30       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.